<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01510782</url>
  </required_header>
  <id_info>
    <org_study_id>1293.1</org_study_id>
    <secondary_id>2011-002251-34</secondary_id>
    <nct_id>NCT01510782</nct_id>
  </id_info>
  <brief_title>Single Rising Dose Study (Intravenous Infusion and Subcutaneous Injection) of BI 655064 in Healthy Male Volunteers</brief_title>
  <official_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses (0.2 mg to 120 mg Administered by Intravenous Infusion and 40 mg to 120 mg Administered by Subcutaneous Injection) of BI 655064 (Buffer Solution for Injection) in Healthy Male Volunteers (Randomised, Single-blind, Placebo-controlled Within Dose Groups, Clinical Phase I Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To investigate safety and tolerability of BI 655064 in healthy male volunteers following
      intravenous infusion of escalating single doses and following subcutaneous injection.
      Exploration of the pharmacokinetics and pharmacodynamics of BI 655064 after single dosing and
      determination of the bioavailability of subcutaneous injections of BI 655064.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in vital signs (blood pressure [BP], pulse rate [PR])</measure>
    <time_frame>up to 70 days post treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in 12-lead ECG (electrocardiogram)</measure>
    <time_frame>up to 70 days post treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>up to 70 days post treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of global tolerability by investigator</measure>
    <time_frame>up to 70 days post treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of local tolerability by investigator</measure>
    <time_frame>up to 70 days post treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum measured concentration of the analyte in plasma</measure>
    <time_frame>up to 1656 hours post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity</measure>
    <time_frame>up to 1656 hours post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve of the analyte in the plasma over the time interval from 0 to the last measurable time point of the dose</measure>
    <time_frame>up to 1656 hours post treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BI 655064 subcutaneous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalating single dose as solution for subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to BI 655064 subcutaneous</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Escalation single dose as solution for subcutaneous injection (Placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 655064 intravenous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalating single dose as solution for intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to BI 655064 intravenous</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Escalating single dose as solution for intravenous infusion (Placebo)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to BI 655064</intervention_name>
    <description>intravenous infusion of escalating doses</description>
    <arm_group_label>Placebo to BI 655064 intravenous</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to BI 655064</intervention_name>
    <description>subcutaneous injection of escalating doses</description>
    <arm_group_label>Placebo to BI 655064 subcutaneous</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 655064</intervention_name>
    <description>intravenous infusion of escalating doses</description>
    <arm_group_label>BI 655064 intravenous</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 655064</intervention_name>
    <description>subcutaneous injection of escalating doses</description>
    <arm_group_label>BI 655064 subcutaneous</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        1. Healthy male subjects

        Exclusion criteria:

        1. Any relevant deviation from healthy conditions
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1293.1.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2012</study_first_submitted>
  <study_first_submitted_qc>January 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2012</study_first_posted>
  <last_update_submitted>October 31, 2013</last_update_submitted>
  <last_update_submitted_qc>October 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

